EMA Assessing Moderna’s Spikevax Against COVID-19 In 6-11 Year-Olds
Phase II Study Showed A ‘Robust’ Response
Moderna says this is the first filing for the vaccine in this age group, and that it will be followed by submissions to other world regulators.
